Since MS is the prototypical inflammatory demyelinating disease of the central nervous system, these results suggest that compound 22 might bind the endogenous RIPK1 in brain tissue in order to exhibit pharmacological activity. This evidence concerns the gene RIPK1 and myeloid sarcoma.